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Structural cortical network 
reorganization associated with 
early conversion to multiple 
sclerosis
C. Tur  1, A. Eshaghi1,2, D. R. Altmann1,3, T. M. Jenkins1, F. Prados  1,4, F. Grussu1,2, 
T. Charalambous1, A. Schmidt5, S. Ourselin4, J. D. Clayden6, C. A. M. G. Wheeler-Kingshott1,7,8, 
A. J. Thompson1,9, O. Ciccarelli1,9 & A. T. Toosy1
Brain structural covariance networks (SCNs) based on pairwise statistical associations of cortical 
thickness data across brain areas reflect underlying physical and functional connections between them. 
SCNs capture the complexity of human brain cortex structure and are disrupted in neurodegenerative 
conditions. However, the longitudinal assessment of SCN dynamics has not yet been explored, despite 
its potential to unveil mechanisms underlying neurodegeneration. Here, we evaluated the changes 
of SCNs over 12 months in patients with a first inflammatory-demyelinating attack of the Central 
Nervous System and assessed their clinical relevance by comparing SCN dynamics of patients with 
and without conversion to multiple sclerosis (MS) over one year. All subjects underwent clinical and 
brain MRI assessments over one year. Brain cortical thicknesses for each subject and time point were 
used to obtain group-level between-area correlation matrices from which nodal connectivity metrics 
were obtained. Robust bootstrap-based statistical approaches (allowing sampling with replacement) 
assessed the significance of longitudinal changes. Patients who converted to MS exhibited significantly 
greater network connectivity at baseline than non-converters (p = 0.02) and a subsequent connectivity 
loss over time (p = 0.001–0.02), not observed in non-converters’ network. These findings suggest SCN 
analysis is sensitive to brain tissue changes in early MS, reflecting clinically relevant aspects of the 
condition. However, this is preliminary work, indicated by the low sample sizes, and its results and 
conclusions should be treated with caution and confirmed with larger cohorts.
GM atrophy is a key determinant of long-term disability in MS1–3. However, the intermediate steps linking brain 
tissue damage to accrual of disability in MS are not well understood and therefore cannot be effectively tackled 
by treatments or used to build accurate predictive models of clinical progression. In this context, it has been 
proposed that the disruption of functional and structural brain networks may be related to these intermediate 
processes leading, eventually, to physical and cognitive disability in MS4.
Among the types of studied brain networks, there are structural covariance networks (SCNs), which are 
based on the anatomical similarity, at the group level, between different cortical areas5–8. Cortical areas sharing 
common functions with evolutionary shared development have greater similarity for macroscopic features than 
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non-functionally related regions9. Thus, the study of the changes in the patterns of morphological similarity in the 
cortex has emerged as a useful tool to examine the link between structural damage and functional consequences10.
SCNs are constructed from the statistical covariance between cortical regions in terms of any morpholog-
ical variable, such as cortical thickness, cortical surface or cortical volume. However, SCNs built based on the 
statistical covariance of thicknesses of different cortical regions are most frequently studied. Thus, the nodes of 
these networks are the different brain areas, and the edge connecting any two of these nodes is determined as the 
correlation in thicknesses between cortical areas forming the two nodes. Because SCNs are strongly influenced by 
congenital and developmental functional relationships between cortical areas, but are also susceptible to acquired 
damage in the cortical GM, the investigation of SCN can provide information complementary to functional and 
diffusion-based connectivity analyses6,7,11.
SCNs have also the potential to provide information complementary to more classical univariate analyses of 
structural damage, such as cortical thinning. Covariance network analysis accounts for inter-regional correlations 
in cortical thickness data and allows us to estimate the actual impact of such correlations on disease progression. 
This implies that SCN analysis is able to better evaluate the complexity of human brain cortex structure than 
classical univariate approaches, where relationships between cortical regions are not taken into consideration. In 
fact, SCN analysis has been applied to several neurodegenerative disorders, revealing neurodegeneration at the 
network level that might be missed at regional-level12.
However, despite the potential of SCN analysis to unveil new mechanisms of neurodegeneration, the longitu-
dinal assessment of SCN dynamics and their pathological relevance have not yet been explored.
We hypothesised that longitudinal SCN analyses in patients at the earliest stages of MS may provide com-
plementary information to conventional cortical GM thickness analysis, revealing important –and otherwise 
hidden– features of GM dynamics. Our aims were to characterise the longitudinal changes in SCN parameters in 
the early CIS, comparing the behaviour of SCNs of CIS patients and age-matched healthy controls, and impor-
tantly, to investigate the clinical relevance of SCNs, through assessing SCN changes in those who converted to 
clinically definite MS within the first year. Our aims were achieved applying robust, computationally intensive 
bootstrapping-based statistical methods to obtain data-driven estimations of confidence intervals of our network 
parameters13, which allowed us to make unbiased statistical inferences. Of note, given the particular group-level 
nature of SCN metrics, such statistical inferences would not have been possible using more conventional statis-
tical approaches.
Results
Descriptive statistics. For this study, we included 21 patients (18 female, mean age [standard deviation, 
SD]: 32.24 [6.18] years) and 7 healthy controls (HCs) (5 female; 30.14 [3.44] years). All subjects included in this 
study belong to a cohort of 28 CIS patients and 10 HCs, whose clinical and demographic features have been pre-
viously reported14–17. We excluded: two HCs because they only had baseline data; one HC and four CIS patients 
because of the low quality of the cortical thickness segmentation; and three CIS patients because they did not 
attend the last follow-up and they had also missed at least one more time point, implying that a single imputation 
method would have not provided reliable enough information.
During follow-up, nine patients presented a second clinical attack suggestive of MS. These patients were 
diagnosed with clinically definite MS (called ‘clinical MS converters’). Three additional patients presented new 
(asymptomatic) lesions, fulfilling the criteria for dissemination in space (DIS) and time (DIT). Thus, the nine 
patients with a second attack plus the three patients fulfilling DIS and DIT criteria through MRI fulfilled the 2010 
McDonald criteria for MS18 (Table 1).
Cortical thickness and other structural imaging data analyses. At baseline, mean (SD) cortical 
thickness was 2.713 (0.135) mm in patients, and 2.751 (0.058) mm in controls. At follow-up, mean (SD) cortical 
thickness was 2.715 (0.087) mm in patients and 2.726 (0.052) mm in HCs. In patients, median lesion loads at 
baseline and follow-up were 1.525 mL (range: 0 to 16.199 mL) and 2.918 mL (range: 0 to 17.038 mL). The main 
locations of the MS lesions are shown in Supplementary Table 1. After adjusting for age, gender and T2 lesion 
load, no significant differences in mean cortical thickness were observed between CIS patients and HCs and base-
line or at one-year follow-up (p = 0.748 and 0.367, respectively). Over time, neither CIS patients: −0.0003 mm/
month (95% CI: −0.003 to 0.003 mm/month), p = 0.822, nor HCs: −0.002 mm/month (−0.004 to 0.0004 mm/
month), p = 0.338, showed a significant change in mean cortical thickness over time. No differences between 
these rates of change were observed either (p = 0.46).
Similarly, no differences in cortical thickness were observed between patients with and without early con-
version to MS at baseline or follow-up (p = 0.5079 and 0.9103, respectively), after adjusting for age, gender and 
T2 lesion load. Additionally, none of the two patient groups showed a significant change in cortical thickness 
over one year: CIS with conversion to MS: 0.001 (−0.005 to 0.007), p = 0.655; CIS without conversion to MS: 
−0.001 (−0.005 to 0.004), p = 0.586. Besides, these rates of change were not significantly different from each 
other (p = 0.4842).
Structural cortical network analysis. All CIS patients vs. HCs. At baseline, no differences were found in 
any of the metrics between all CIS patients and HCs (Fig. 1 and Supplementary Figure 1).
When looking at the changes over time, CIS patients’ network tended to show an overall decrease in connec-
tivity and significant differences in several metrics were observed between patients’ and controls’ networks at 3 
and, especially, at 6 months of follow-up: mean nodal strength (p < 0.001), mean clustering coefficient (p = 0.01), 
mean shortest path (p < 0.001), global efficiency (p = 0.01) and local efficiency (p = 0.01) (Fig. 1). Yet none of the 
12-month longitudinal changes in either patients’ or controls’ networks reached statistical significance (Table 2).
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Supplementary Figure 2 shows the bootstrap distributions used to ascertain the statistical significance of the 
12-month changes in network parameters and, as mentioned, no differences between groups were observed. 
Supplementary Table 2 shows the point estimates and bootstrap-based 95% CIs for baseline and 12-month net-
work parameters: only the mean shortest path was significantly different (i.e. greater, p < 0.001) in patients than 
controls, at 12-month follow-up.
CIS patients with vs. without clinical conversion to MS. At baseline, the network of CIS patients who later clini-
cally converted to MS during the follow-up showed features of greater nodal connectivity, i.e. significantly greater 
mean nodal strength (p = 0.02) and clustering coefficient (p = 0.02), and features of better network integration, 
i.e. lower mean shortest path (p < 0.001) and greater global (p = 0.02) and local (p = 0.02) efficiency, than the 
network of non-converters, who showed similar values to HCs’ network (Fig. 2).
Over one year, clinical MS converters’ network showed significant changes in all metrics related to nodal 
connectivity: mean nodal strength decreased by 10.18 units (bootstrap-based 95% CI: −16.22 to −0.87), 
p = 0.02; mean clustering coefficient decreased by 0.16 units (−0.27 to −0.01), p = 0.02; and all metrics related 
to nodal distance: both global (−0.12 (−0.20 to −0.02), p = 0.01) and local efficiency (−0.15 (−0.25 to −0.01), 
p = 0.02) decreased, whereas mean shortest path increased (0.56 (0.19 to 0.80), p = 0.001) over one year. Instead, 
non-converters network did not show any significant changes over time, except for the mean shortest path, which 
decreased over 1 year (p = 0.01), mirroring HCs’ network behaviour. The rates of change over time of the two 
networks were all strongly significantly different from each other (p-values from 0.01 to <0.001), except for the 
change in modularity coefficient (p = 0.5) (Table 3 and Fig. 2). Supplementary Figures 3 and 4 show the bootstrap 
distributions used to ascertain the statistical significance of the parameters. Supplementary Table 3 shows the 
point estimates and bootstrap-based 95% CIs for baseline and 12-month network parameters.
When analysing regional changes in those metrics that admit a node-level analysis, i.e. nodal strength, cluster-
ing coefficient and local efficiency, the changes in the network of patients with an early conversion to MS showed 
a very similar pattern to those network changes observed for all patients together. Instead, network changes of 
those who did not convert were similar to changes in HCs’ network (Fig. 3). Please see Table 4 for a summary of 
these results.
All HCs All CIS
HCs vs. CIS, 
p-value CIS-CISa CIS-MSb
CIS-CISa vs. CIS-
MSb, p-value
N finally included 7 21 — 12 9 —
Age at study onset, mean 
(SD)
30.143
(3.436)
32.238
(6.180) p = 0.405
e 30.917
(5.368)
34
(7.053) p = 0.268
e
No. females 5 18 p = 0.393f 10 8 p = 0.719f
Cortical thickness at 
baseline, mean (SD)
2.751
(0.058)
2.713
(0.135) p = 0.748
g 2.748
(0.075)
2.667
(0.184) p = 0.508
g
Cortical thickness at 12 m, 
mean (SD)
2.726
(0.052)
2.715
(0.087) p = 0.367
g 2.750
(0.060)
2.672
(0.100) p = 0.910
g
Lesion volume at baseline, 
median (range) —
1.525 mL
(0 to 16.199 mL) —
0.534 mL
(0 to 3.516 mL)
5.260 mL
(1.525 to 16.199 mL) p = 0.001
e
Lesion volume at 3 months, 
median (range) —
1.828 mL
(0 to 18.536 mL) —
0.631 mL
(0 to 2.918 mL)
6.113 mL
(1.828 to 18.536 mL) p = 0.001
e
Lesion volume at 6 months, 
median (range) —
2.101 mL
(0 to 17.816 mL) —
0.571 mL
(0 to 2.716 mL)
5.397 mL
(1.521 to 17.816 mL) p = 0.002
e
Lesion volume at 12 
months, median (range) —
2.918 mL
(0 to 17.038 mL) —
0.756 mL
(0 to 4.891 mL)
5.322 mL
(2.246 to 17.038 mL) p = 0.005
e
DISc at baseline, no. — 10 — 4 6 p = 0.130f
DISc at 3 months, no. — 10 — 4 6 p = 0.130f
DISc at 6 months, no. — 9 — 3 6 p = 0.078f
DISc at 12 months, no. — 12 — 5 7 p = 0.094f
DISc and DITc,d at baseline, 
no. — 0 — 0 0 p > 0.99
f
DISc and DITc,d at 3 
months, no. — 3 — 0 3 p = 0.031
f
DISc and DITc,d at 6 
months, no. — 6 — 2 4 p = 0.202
f
DISc and DITc,d at 12 
months, no. — 9 — 3 6 p = 0.058
f
Table 1. Demographical, clinical and MRI characteristics of the study cohort. aPatients who did not have a 
second attack during the follow-up; bpatients who had a second attack during the follow-up; caccording to the 
2010 Revisions of the McDonald Criteria; dpatients did not undergo a whole-brain T1-weighted scan after 
Gadolinium injection. Therefore, it was not possible to assess whether gadolinium-enhancing lesions were 
coexisting with non-gadolinium-enhancing lesions, at any time point; etwo-sample t-test; fchi-square test; 
glinear regression adjusting for age, gender and T2 lesion load. Abbreviations: CIS: clinically isolated syndrome; 
DIS: dissemination in space; DIT: dissemination in time; HCs: healthy controls; SD: standard deviation.
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A post-hoc analysis comparing the network of patients who were diagnosed with McDonald MS (i.e. either 
they had a second clinical attack or fulfilled the criteria for DIS and DIT during the follow-up, N = 12) with 
the network of those not fulfilling the diagnosis of McDonald MS (N = 9) was also performed. This compar-
ison revealed very similar results to those obtained with the comparison of clinical MS converters (N = 9) vs. 
non-clinical MS converters (N = 12), as shown in Supplementary Tables 4 and 5.
Discussion
In this longitudinal study, we provide evidence, for the first time, of reorganisational changes in SCNs of CIS 
patients who experience an early conversion to clinically definite MS, in the absence of detectable cortical atrophy. 
These results suggest that SCN analysis may be more sensitive to those changes occurring in the cortical GM at 
the earliest stages of the disease than conventional, regression-type (average-based) approaches of structural data. 
Besides, these results indicate that SCN changes may be clinically relevant.
Although structural covariance networks and cortical thickness data are indirectly related8, structural net-
works reflect global aspects of the data that cannot be captured by conventional analyses of cortical thickness: 
SCNs reflect the associations between cortical regions, and their longitudinal evaluation hence reflects how these 
associations change over time, revealing hidden patterns in GM dynamics not observable with classical (lin-
ear regression-type) approaches8. However, despite numerous longitudinal analyses reported in the literature of 
cortical thickness data to assess disease progression in neurodegenerative conditions19–21, this has not yet been 
assessed through SCNs. In our study, despite the absence of cortical atrophy in patients, we observed features of 
increased network connectivity and network integration at baseline among those patients who later converted 
to MS. This was followed by a clear trend towards an overall loss of network connectivity over time and a dete-
rioration of the network’s ability to integrate information, which was statistically significant in those patients 
who converted to MS during the follow-up. None of these reorganisational changes, either at baseline or during 
follow-up, were observed in non-converters’ or HCs’ networks. These results suggest that SCN analyses may be 
Figure 1. Network metrics over time in all CIS patients and HCs. This figure shows the evolution of network 
metrics over time for patients’ and controls’ networks, with the bootstrap standard errors. Although at follow-up 
only the mean shortest path was significantly different between patients’ and controls’ networks, at six-month 
follow-up, most of the metrics were significantly different between the two networks; *p < 0.05; **p < 0.01; 
***p < 0.001.
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more sensitive to pathological processes occurring at these very early stages of MS than conventional analyses of 
cortical thickness data. Of note, the experimental groups of our study were biased towards females, indicating 
they were representative of the population of MS, which mainly affects females, especially with the relapse-onset 
phenotypes. On the other hand, in our analyses, we had initially adjusted our cortical thickness data for age and 
gender. This step was performed to ensure that the potential confounding effect of gender in our results was min-
imised or even eliminated.
Importantly, these results are in line with the idea that SCN analysis provides complementary information to 
more classical analyses of structural damage because they account for aspects of the data that conventionally were 
considered, at most, as nuisance parameters. In SCN analysis, instead, such correlations are no longer nuisance 
parameters to be allowed for when computing the uncertainty with which a given parameter of interest is esti-
mated, but they are the main parameters of interest.
Disruption of SCNs was first described in MS in 2009 by He et al.22, and in 2014, Tewarie et al.11, found that 
SCNs disruption in MS was echoed by changes in functional networks obtained through magnetoencephalog-
raphy. However, the cross-sectional design of those studies did not allow the characterisation of the dynamics of 
such disruption, as opposed to our study, where we could observe that the disruption occurred after an initial 
explosion of SCN connectivity, suggesting the presence of a network reorganisation after an initial perturbation, 
which would have been overlooked should we not had used a longitudinal design. Importantly, our longitudi-
nal design also allowed us to evaluate the clinical relevance of such reorganisational network changes, which 
would not have been possible if we had only considered a single time point. Notably, such initial explosion of 
SCN connectivity observed in patients and especially in patients who later on converted to MS was mainly at 
the expense of negative correlations across cortical areas, as can be observed in Fig. 5. As time went by, such 
strong correlations tended to disappear, especially in the MS converters’ network. At the end of the follow-up, 
both patients’ networks had lower connectivity and global and local efficiency than the HCs’ network (although 
non-significantly) (Supplementary Tables 6–9).
Structural covariance networks are built upon the assumption that, in the healthy brain, two brain cortical 
areas showing morphological similarity in terms of their cortical thickness are physically and/or functionally 
connected5,8,23,24. However, in the diseased brain, the interpretation of modified or disrupted covariance networks 
is not straightforward. The time scale for the shaping of the covariance networks in the healthy brain is believed 
to span many years7, and it is therefore unlikely that their abnormal configuration or disruption, especially if 
observed over the short time period of one year, can be attributed to a disease-related damage in the underlying 
physical or functional connection between cortical areas. Besides, the fact that our cortical networks were built 
using cortical thickness values adjusted for lesion load (and other confounders) makes it unlikely that the disrup-
tion of WM tracts is the cause of the alteration in the correlations between cortical areas. On the other hand, it 
is also unlikely that the initially increased covariance network connectivity observed in those patients who later 
on converted to MS and its subsequent disruption over time are unrelated events. This statement would be sup-
ported by the presence of strikingly similar values of SCN connectivity at one-year follow-up in converters and 
non-converters. We speculate that these early reorganisational changes could reflect the presence of a microscopic 
inflammatory cortical process around the time of the CIS in those who will experience early future conversion, 
leading to an initially more homogeneous cortex among future MS converters manifesting as greater connectivity. 
Importantly, all cortical thickness measures used to build SCNs had been adjusted for white matter lesion load 
at baseline, implying that any presence of cortical inflammation at the time of the CIS must have behaved inde-
pendently of macroscopic white matter lesion load. However, since we used 1.5 T scans, we could not assess the 
CIS patients (all) HCs
Patients vs. HCs, 
estimated p-value
1. Measures of nodal connectivity
Mean nodal strength, estimated value (bootstrap-based 95% CI), p-value
Change from baseline to 1 year −3.62 (−12.29 to 2.19), p = 0.3 −0.58 (−3.37 to 2.03), p = 0.7 0.50
Mean clustering coefficient, estimated value (bootstrap-based 95% CI), p-value
Change from baseline to 1 year −0.06 (−0.19 to 0.02), p = 0.15 −0.01 (−0.05 to 0.04), p = 0.8 0.30
2. Measures of nodal distance
Mean shortest path, estimated value (bootstrap-based 95% CI), p-value
Change from baseline to 1 year 0.36 (−0.13 to 0.89), p = 0.2 0.03 (−0.06 to 0.13), p = 0.6 0.25
Global efficiency, estimated value (bootstrap-based 95% CI), p-value
Change from baseline to 1 year −0.05 (−0.14 to 0.02), p = 0.15 −1.46 * 10−4 (−0.03 to 0.03), p = 0.99 0.20
Mean local efficiency, estimated value (bootstrap-based 95% CI), p-value
Change from baseline to 1 year −0.06 (−0.17 to 0.01), p = 0.15 −0.005 (−0.05 to 0.04), p = 0.9 0.25
3. Measures of network organisation
Modularity coefficient (bootstrap-based 95% CI), p-value
Change from baseline to 1 year 0.02 (−0.01 to 0.06), p = 0.2 0.0054 (−0.03 to 0.04), p = 0.7 0.60
Table 2. One-year changes in SCN parameters, in CIS patients and HCs. Comparison between CIS patients and 
HCs was made looking at the 95% CI. See main text for full details on the methods used. Significant p-values 
are indicated with bold letters. Abbreviations: CI: confidence interval; CIS: clinically isolated syndrome; FU: 
follow-up; HCs: healthy controls.
www.nature.com/scientificreports/
6SCIeNtIFIC REPORTS |  (2018) 8:10715  | DOI:10.1038/s41598-018-29017-1
presence of cortical lesions in our patients25, so we could not explore this hypothesis further. Yet we did explore, in 
a post-hoc analysis, the effect of the lesion load on the actual network metrics (Supplementary Tables 10–13). This 
analysis showed that the metrics of the HCs’ network were almost unchanged, as expected, when using cortical 
thickness unadjusted for lesion load, though adjusted for age, gender and mean cortical thickness (see Methods 
for full details), as compared with the ones obtained with fully adjusted cortical thickness values. Instead, the 
metrics of the patients’ networks, especially the networks for all CIS patients and clinical MS converters, tended to 
show, in general, lower connectivity than the corresponding adjusted networks. This was especially evident for the 
12-month follow-up networks. Therefore, this implied that, in general, differences between patients’ and controls’ 
networks or between converters’ and non-converters’ networks increased, as compared to fully adjusted cortical 
networks. This supports the idea that the explosion of connectivity at onset was indeed probably associated with 
greater inflammation. Future studies with high-field multi-modal MR images are warranted to understand the 
pathological substrate underlying cortical network changes in early MS.
When patients were divided into two groups – those who clinically converted and those who did not convert 
to MS within the one-year follow-up, SCN analysis revealed striking differences between groups: at baseline, 
converters’ network showed signs of greater connectivity than non-converters’ network. However, during the 
follow-up, whereas MS converters exhibited longitudinal changes consistent with progressive disruption of SCNs, 
the non-converters’ network overall showed minimal, non-significant, changes over time, mirroring the behav-
iour of HCs’ network. This is the first time that clinical relevance of covariance cortical networks in MS has been 
reported from longitudinal data. Reassuringly, similar results were found when MS converters were compared to 
non-MS converters according to the 2010 McDonald criteria18 (Supplementary Tables 4 and 5).
Importantly, the similarity between all patients’ and MS converters’ networks was also reflected in the regional 
distribution of nodal connectivity changes, reinforcing the concept that SCN changes may be clinically rele-
vant: losses of nodal strength, clustering coefficient and local efficiency seemed to be more obvious in pre- and 
post-central gyri and the paracentral lobule, bilaterally, not only in (all) patients’ network, but also in the MS con-
verters’ network, as shown in Fig. 3. Interestingly, these central regions, which in this context would indicate those 
with greatest loss of similarity with other cortical regions, have been also identified, in diffusion-based networks, 
as hubs and rich-club members26. Rich-club members are nodes with a high number of anatomical connections, 
preferentially involving other highly connected nodes, which are known to play key roles in the hierarchical 
organisation of the human brain26 and seem to possess specific microstructural features27.
Although SCN analyses cannot elucidate the biological processes underlying the observed changes in covari-
ance patterns, this does not reduce the importance of our findings. Our study may have revealed a crucial aspect 
of MS pathology detectable in those who convert early to MS, indicating its clinical relevance, and only when an 
analysis of the covariance across cortical regions’ thickness is performed. Besides, although observed at the group 
level (because of the nature of SCNs), our results provide valid grounds for the generation of new hypotheses 
about unexplored mechanisms underlying disability progression. In this case, it is likely that the ultimate cause 
associated with such cortical network reorganisational changes is also related to conversion to MS, rather than 
being the presence of such SCN changes per se the factor actually conferring a higher risk for conversion. For 
instance, a post-hoc analysis comparing patients with supratentorial lesions only and patients with supra- and 
infratentorial lesions, at any time during the 12-month follow-up period, revealed that the network of those 
patients with both supra- and infratentorial lesions behaved similarly to that of patients with an early conversion 
to MS (Supplementary Tables 14 and 15). Whereas this reflects the known relationship between presence of 
Patients with clinical MS 
conversion
Patients without clinical MS 
conversion
Patients with vs. without 
clinical MS conversion, 
estimated p-value
1. Measures of nodal connectivity
Mean nodal strength, estimated value (bootstrap-based 95% CI), p-value
Change from baseline to 1 year −10.18 (−16.22 to −0.87), p = 0.02 2.39 (−1.03 to 7.52), p = 0.3 0.01
Mean clustering coefficient, estimated value (bootstrap-based 95% CI), p-value
Change from baseline to 1 year −0.16 (−0.27 to −0.01), p = 0.02 0.03 (−0.02 to 0.11), p = 0.4 0.01
2. Measures of nodal distance
Mean shortest path, estimated value (bootstrap-based 95% CI), p-value
Change from baseline to 1 year 0.56 (0.19 to 0.80), p = 0.001 −0.28 (−0.58 to −0.07), p = 0.01 <0.001
Global efficiency, estimated value (bootstrap-based 95% CI), p-value
Change from baseline to 1 year −0.12 (−0.20 to −0.02), p = 0.01 0.03 (−0.01 to 0.09), p = 0.2 0.01
Mean local efficiency, estimated value (bootstrap-based 95% CI), p-value
Change from baseline to 1 year −0.15 (−0.25 to −0.01), p = 0.02 0.03 (−0.02 to 0.10), p = 0.3 0.01
3. Measures of network organisation
Modularity coefficient (bootstrap-based 95% CI), p-value
Change from baseline to 1 year 0.03 (−0.02 to 0.07), p = 0.5 0.01 (−0.02 to 0.03), p = 0.8 l 0.5
Table 3. One-year changes in SCN parameters, in CIS patients with and without clinical conversion to MS. 
Comparison between patients with and without MS conversion was made looking at the 95% CI. See main 
text for full details on the methods used. Significant p-values are indicated with bold letters. Abbreviations: CI: 
confidence interval; CIS: clinically isolated syndrome; FU: follow-up; HCs: healthy controls.
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infratentorial lesions and a worse prognosis, it might also reflect a possible mechanism through which the pres-
ence of infratentorial lesions entails this worse prognosis. In any case, further studies combining SCN analysis 
and other connectivity and structural imaging methods, such as resting-state fMRI, high-resolution magnetisa-
tion transfer imaging28 and diffusion-weighted imaging29, are required to elucidate this point. Importantly, SCN 
methodology can also help assess how the presence of certain well-known risk factors, such as smoking habit or 
low vitamin D levels, which many times can only be assessed at the group level, or how the implementation of 
population-level measures, such as education programmes about healthier diet or habits, can modify multiple 
pathological aspects of the disease, at once (i.e. in a multivariate manner) and straightforwardly.
Covariance networks are built based on correlations at the group level. This means that classical statistical 
methods such as t-test or regression-type approaches cannot assess differences between groups or between time 
points. Even if for many network metrics, in particular for those implying node-level estimations (i.e. nodal 
clustering coefficient or nodal local efficiency), mean values are estimated and there is a network-level variability 
based on the values estimated for the different nodes, this variability could not be used to carry out statistical tests 
based on the group variance given the strong dependence of such values within the network. In this study, we 
utilised a bootstrap-based approach to estimate the limits of the 95% confidence intervals for the parameters that 
define the networks (e.g. mean nodal strength), needed to estimate whether two networks are actually different or 
whether an observed change over time is statistically significant. Bootstrap-based approaches rely on the variabil-
ity of the original data to estimate the confidence intervals, without making any distributional assumptions13,30. 
Thus, they are much more robust and conservative than classical inference methods, implying that the risk of type 
I error is actually below the nominal 5% and that the changes we observed in the parameters of the converters’ 
network are likely to be genuine. Of note, the use of robust bootstrapping techniques to assess the uncertainty 
of estimated parameters is particularly relevant when these parameters are derived from a given network, where 
it would not be correct to make parametric assumptions based on the distribution of individual nodal metrics 
within the same network to estimate the uncertainty of the network-defining parameter30.
Although SCN analysis challenges the possibility of drawing conclusions at the individual level, it appears 
as an attractive and straightforward method to assess the relationship between complex multi-dimensional 
Figure 2. Network metrics over time in MS converters and non-MS converters. This figure shows the evolution 
of network metrics over time for MS converters and non-MS converters, with the bootstrap standard errors. 
*p < 0.05; **p < 0.01; ***p < 0.001. Please look at Table 3 for more details.
www.nature.com/scientificreports/
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predictors, such as cortical thickness data, and a given clinical outcome. Although some authors have proposed 
individualised covariance networks using cortical thickness data to study neurodegeneration31,32, these have not 
yet been published in MS. Besides, the relationship between individual-level and group-level network disruptions 
in other neurodegenerative conditions has not yet been assessed either.
A further methodological consideration relates to the fact that thickness values from each region were treated 
equally in the statistical analysis, as previous studies have reported8. This implies that we did not account for the 
different volumes of the brain areas, although this might not be relevant in our case, since we were interested in 
the associations between cortical thicknesses, which are those that are believed to reflect underlying physical or 
functional connections8. Another consideration is that we constructed the weighted graphs using the absolute 
values of the Pearson’s correlation coefficients of the covariance matrices, as described previously8. Although a 
visual inspection of the correlation matrices at baseline and at 12-month follow-up suggest that increased baseline 
connectivity in patients (and especially in early MS converters) was mainly at the expense of negative correlations, 
a formal connectivity analysis for positive and negative graphs was not performed in this study. Although it may 
be interesting to assess independently networks derived from positive and negative correlations, this was beyond 
the scope of this study. This analysis would also pose other challenges with methodology and interpretation and 
may deserve attention in future studies.
Another consideration refers to the fact that we used the 2010 revisions to the McDonald Criteria18 for the 
diagnosis of McDonald MS, instead of the most recent ones, published in 201833. The 2010 revisions to the 
McDonald Criteria for the diagnosis of MS were the current criteria for the diagnosis of MS when this study was 
designed, in 2015. We acknowledge that the results might be slightly different from those that we present now if 
we had used the 2017 revisions of the McDonald criteria.
Finally, the small sample size, especially in controls, is an important limitation of the study. Although the 
lack of significant changes in controls could have theoretically been attributed to controls’ smaller sample size, 
when we compared MS converters with non-converters, where also covariance networks were built with small 
sample sizes, MS converters showed statistically significant changes that were not observed in non-converters. 
Importantly, because all our inferences related to SCNs were made through robust bootstrap-based approaches, 
it is possible that the observed significant results are in fact genuine. However, it is also true that the sample size 
was low even for using a bootstrap approach, therefore the robustness of the network of anatomical covariance 
analysis was not guaranteed, and this could have biased the statistical results. We therefore consider these results 
as preliminary and acknowledge the need to replicate them in larger cohorts.
In conclusion, SCNs of patients with their first inflammatory-demyelinating episode of the CNS, and espe-
cially of those who convert to MS, show clear reorganisational changes in the absence of detectable cortical 
All CIS vs. 
HCs
CIS with vs. without 
MS conversion
CIS with MS 
conversion vs. HCs
CIS without MS 
conversion vs. HCs
Mean nodal strength at baseline
Baseline No Yes No No
Change over time No Yes No No
Follow-up No No No No
Mean clustering coefficient
Baseline No Yes No No
Change over time No Yes No No
Follow-up No No No No
Mean shortest path
Baseline No Yes No Yes
Change over time No Yes Yes Yes
Follow-up Yes No No No
Global efficiency
Baseline No Yes No No
Change over time No Yes Yes No
Follow-up No No No No
Mean local efficiency
Baseline No Yes No No
Change over time No Yes No No
Follow-up No No No No
Modularity coefficient
Baseline No No No No
Change over time No No No No
Follow-up No No No No
Table 4. Summary table of the differences between groups. This table indicates whether there were significant 
differences between groups (indicated as ‘Yes’) or not (indicated as ‘No’). Abbreviations: CIS: clinically isolated 
syndrome; HCs: healthy controls; MS: multiple sclerosis.
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atrophy. Thus, covariance network analysis not only is more sensitive than conventional analysis of structural 
data but also seems to unveil clinically relevant aspects of this condition. Of note, the low sample size indicates 
this is preliminary work and the results and conclusions derived from it should be taken with caution and be 
confirmed in larger cohorts. In any case, the fact that covariance network analysis can be applied retrospectively 
to large cohorts of patients who have undergone T1-weighted scans within other protocols makes this technique 
a powerful and straightforward method to help us understand pathological processes underlying disease pro-
gression in MS.
Methods
Subjects. We included consecutive patients with a diagnosis of optic neuritis as their first demyelinating 
attack of the central nervous system (i.e. CIS) within the previous four weeks. All patients underwent clinical 
assessments, at baseline, 3, 6 and 12 months. At each visit, apart from visual assessments, we recorded whether 
the patient had suffered a second clinical attack. Additionally, we also recorded the presence of new white matter 
T2 lesions and whether these occurred in different locations, fulfilling dissemination in time and space crite-
ria and therefore fulfilling the diagnostic criteria of MS according to the 2010 revisions to the McDonald criteria18 
Figure 3. Estimated monthly changes in nodal metrics for all groups. This figure shows the estimated monthly 
changes in the three node-level metrics: (A) nodal strength, (B) clustering coefficient and (C) local efficiency. In 
this figure, the size of the nodes indicates the absolute value of the change: bigger nodes have greater changes, 
in either direction, and smaller nodes have changes close to zero. Instead, the color of the nodes indicates the 
direction of the change: redder nodes indicate positive changes (increase) and bluer nodes indicate negative 
changes (decrease). The behavior over time of all-CIS network differed from that of HCs’ network, yet these 
differences did not reach statistical significance (see Table 2). This different behavior was mirrored by the two 
patient groups: whereas the non-converters’ network only showed minimal changes over time, the converters’ 
network showed an overall decrease in nodal strength, clustering coefficient and local efficiency. Of note, the 
regional distribution of nodes with greatest changes over time (pre- and post-central gyri and paracentral 
lobule, bilaterally) was similar for the all-CIS and the converters’ networks. Abbreviations: CIS: clinically 
isolated syndrome; HCs: healthy controls.
Figure 4. Study pipeline. This is the study pipeline that we followed to obtain the network parameters at each 
time point and also the changes over 1 year. For each parameter and time point, and for each parameter change, 
1000 bootstrap samples were used to compute the 95% Confidence Intervals. See main text for more details. 
Abbreviations: CIS: clinically isolated syndrome; HCs: healthy controls; FU: follow-up.
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(Table 1). This has been reported elsewhere16,17. We also included a group of age-matched healthy controls (HCs). 
All participants underwent MRI scans. The study was approved by the Ethics Committee of the National Hospital 
for Neurology and Neurosurgery, part of the University College London Hospitals NHS Foundation Trust. This 
is an observational study and all methods were performed in accordance with the relevant guidelines and regula-
tions. All participants provided informed written consent.
MRI analysis. All MRI scans were performed with a 1.5 T GE Signa Echospeed MRI (Milwaukee, WI) scan-
ner. The scanner maximum gradient strength was 33 mT m−1.
Acquisition of brain structural scans. For all subjects, we acquired the following images at baseline, 3, 6 and 12 
months: axial oblique, proton-density (PD), dual echo, fast spin echo images (resolution: 0.9 × 0.9 × 5 mm3), 
as previously described14–17; axial three-dimensional fast prepared spoiled gradient recall (3D-FSPGR, 3D 
T1-weighted) (resolution: 1.2 × 1.2 × 1.2 mm3).
T2 hyperintense WM lesions were manually outlined by an experienced observer from the PD-weighted 
images using the semi-automated edge finding tool from JIM (JIM v6.0, Xinapse systems, Aldwincle, UK, http://
www.xinapse.com). PD-weighted lesion masks were co-registered to the 3D-T1 images using a pseudo-T1 image 
generated by subtracting the PD from the T2-weighted image34. Lesion masks were transformed from native 
space to 3DT1 space. The 3DT1 images were filled using a non-local patch match lesion filling technique35.
Measurement of cortical thickness. We calculated cortical thicknesses for 68 bilateral brain cortical areas using 
the FreeSurfer version 5.3 longitudinal stream36, the technical details of which have been explained elsewhere36–38. 
Briefly, this included skull-stripping, intensity normalisation, non-linear registration to Talairach space, segmen-
tation, estimation of brain surfaces, and surface parcellation. We visually assessed the final segmentation, and 
re-ran the pipeline after manual correction in cases of incorrect surface estimation. To perform unbiased longi-
tudinal image analysis, we created a symmetric within-subject template39. Next, all the steps were re-initialised 
for each time point using the common information to increase reliability and statistical power36. We extracted 
cortical thickness values for each cortical parcellation according to Desikan-Killiany atlas38.
Structural covariance network analysis. Construction of weighted structural covariance networks (Fig. 5): We 
constructed two SCNs, one at baseline and one at 12-month follow-up, for each of these four groups – a) HCs, 
b) all CIS patients, c) MS-converter CIS patients and d) non-converter CIS patients, as follows (of note, although 
SCNs were also built at 3- and 6-month follow-up, the main analysis involved only baseline and 12-month 
follow-up SCNs):
 1) In 3 patients who did not attend the 12-month follow-up but who attended the 0, 3 and 6-month time 
points, cortical thickness at 12-month follow-up was imputed using each patient’s cortical thickness trajec-
tory, i.e. a single imputation technique based on simple linear regression.
 2) Because we were interested in knowing the relationships between cortical thickness values across regions 
whilst adjusting for the effects of possible confounders, we removed variability in the cortical thickness 
data related to lesion load, cortical atrophy, age or gender, all cortical thickness values, for all subjects and 
time points, regressing all cortical thickness values at once over baseline lesion load and baseline cortical 
thickness, age and gender. Total intracranial volume (TIV) obtained through GIF segmentation40 of the 
T1-weighted images was also explored as a covariate. Yet, given its potential association with age and gen-
der, it was only kept if significant at 5% level, to avoid collinearity. The residuals of these regression models 
were considered the new, adjusted, cortical thickness values to be used in subsequent steps8. For this step, 
controls were assigned a lesion load equal to zero mL, as previously performed17,41,42, to be able to obtain 
the residuals for controls through the same regression model as that used to obtain patients’ residuals. This 
allowed us to maintain the original relationships between patients and controls. The assumptions of the 
linear regression were checked through the analysis of the residuals.
 3) Pairwise correlation matrices using adjusted cortical thickness values, with Pearson’s correlation coefficient 
as the association measure, were obtained for each group (i.e. CIS patients, HCs, CIS patients with early 
conversion to MS and CIS patients without early conversion to MS), at baseline and at 12-month fol-
low-up, using MATLAB (The MathWorks, Inc., Natick, Massachusetts, USA) (Fig. 4).
 4) Since we aimed to build weighted networks reflecting the strength of the correlation regardless of whether 
there was a positive or negative association8, we obtained correlation matrices with the absolute value of 
Pearson’s correlation coefficients.
Obtaining network topological metrics: For each weighted matrix, considered as the numerical representation 
of a network with 68 nodes (i.e. 68 cortical areas) and edges indicating the strength of the connection between 
two cortical areas, we obtained the following network topological metrics at the network level. That is, for each 
metric, we obtained a value for each network (i.e. for each group and time point). We used the freely available 
Brain Connectivity Toolbox43 (https://sites.google.com/site/bctnet/) in MATLAB. The metrics were divided into 
three groups:
 1. Metrics of nodal connectivity: mean nodal strength and mean clustering coefficient
These metrics describe the connectivity of each node in the network. Mean nodal strength is the average,  
across all nodes, of the nodal strength, defined as the sum of the correlation coefficients of the edges  
emerging from a given node. Thus, a node with a high strength indicates that the node is very well 
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connected, and a network with high mean nodal strength indicates a very well-connected network. 
Importantly, in this context, highly connected networks indicate a high degree of similarity across cortical 
regions.
Nodal clustering coefficient reflects the connectivity among the neighbours of a given node, and can be 
understood as the probability that each pair of nodes that are connected to a given node are also connected 
among themselves. It can be defined as in [1]:
=i Number of pairs of node i s neighbours that are connected
Number of pairs of node i s neighbours
Clustering coefficient of node ’
’ (1)
Therefore, the mean clustering coefficient is the average clustering coefficient across all nodes of the 
network44. In this context, a network with a high mean clustering coefficient would indicate that cortical 
regions have, in general, strong similarities in terms of cortical thickness with neighbour regions.
 2. Metrics of network integration: mean shortest path, global efficiency and local efficiency
These metrics describe the ability of the network to efficiently integrate information across nodes. Smaller 
values of mean shortest path infer more efficient information transfer between nodes and greater informa-
tion integration within the network45. Mean shortest path (or characteristic path length, L) is the average of 
the shortest path lengths between all pairs of nodes in the network43, and can be defined as in [2]:
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− ≠N
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where N is number of nodes in the network; li is the average shortest path from node i to all other nodes; 
and lij is the shortest path length from node i to node j.
Global efficiency (Eglob) is the reciprocal of the harmonic mean of the shortest path lengths of the entire 
network45, and is defined as in [3]:
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where L′ is the harmonic mean of the mean shortest path; N is number of nodes in the network; and lij is 
the shortest path length from node i to node j.
Local efficiency, which is a node-level metric of integration of information, is the reciprocal of the harmon-
ic mean of the shortest path lengths of the subgraph (i.e. subnetwork) defined by the neighbours of a given 
node45. Local efficiency of node i (Eloc (i)), is defined as in [4]:
∑=
− ∈
E i
N N l
( ) 1
( 1)
1 ,
(4)
loc
G G j h G jh,i i i
where Gi is the subnetwork including all nodes that are neighbours of node i; NGiis the number of nodes 
belonging to subnetwork Gi; and ljh is the shortest path length from node j to node h belonging to subnet-
work Gi.
Figure 5. Correlation matrices. This figure shows the correlation matrices for each one of the groups (all CIS, 
HCs, CIS with early conversion, CIS without early clinical conversion), at baseline and at follow-up. From these 
correlation matrices, we extracted the absolute values of the correlations and built the weighted graphs, used to 
obtain network metrics. Abbreviations: CIS: clinically isolated syndrome; HCs: healthy controls; MS: multiple 
sclerosis.
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Higher global and local efficiency values indicate greater ability to integrate information, globally and 
locally, respectively. Mean local efficiency is the across-node average of local efficiency values of the nodes 
of the network43.
 3. Metric of network organisation: modularity coefficient
Modularity coefficient (ModC) assesses how groups of nodes are clustered in local groups. That is, ModC, 
describes how well a network can be subdivided into groups of nodes (i.e. modules), highly correlated 
among each other, creating small communities inside the network.
Statistical analysis. Descriptive and structural imaging data analyses. Descriptive statistics are reported as 
mean (standard deviation [SD]) or median (range), depending on the nature of the variable.
We assessed changes in mean cortical thickness over one year as part of the preliminary analysis using 
mixed-effects models, where ‘mean cortical thickness’ was the dependent variable and ‘time’, a ‘binary group indi-
cator’ (i.e. patient/control) and an interaction term such as ‘time X group indicator’ were the main explanatory 
variables. Whenever the interaction term was significant, it was assumed that the rate of change in cortical thick-
ness differed between the two groups. All models were adjusted for age, gender and lesion load at baseline (HCs 
were assigned lesion load equal to zero). For the final analyses, total intracranial volume was not included among 
the covariates: it was not significant in any of the models and its introduction did not change the direction or size 
of the effects of the other covariates. Mixed-effects models allowed for repeated measures within the same sub-
ject17,46 and their random structure consisted of a random intercept (for each subject) and random slope (for time, 
which was nested in ‘subject’). Whenever residuals from mixed-effects regression models showed deviation from 
normality, 95% confidence intervals (95% CI) and p-values were obtained using bias-corrected non-parametric 
bootstrap with 1000 replicates.
All these statistical analyses were carried out with Stata 14.1.
SCN analysis in all CIS patients versus healthy controls. Since all network parameters were obtained at the net-
work level, i.e. we had a value for each network, classical statistical approaches could not be used to compute the 
95% confidence intervals (95% CI) of the metric values at baseline and their changes over time, so we employed a 
bootstrap-based approach with these steps:
 1. For each network metric, we initially obtained our baseline value and 12-month follow-up value. From 
the subtraction of these two, we obtained the change in that network. These were our original estimates for 
baseline, 12-month follow-up and change values.
 2. For the groups of CIS patients and HCs, we then created 1000 bootstrap samples (i.e. random samples of 
n subjects chosen –allowing sampling with replacement– from each group, being n = sample size of the 
original group).
 3. In each bootstrap sample, covariance matrices for baseline and follow-up values were computed using 
exactly the same methodology as the one used with the original group.
 4. From each covariance matrix, network topological measures were computed, for baseline and 12-month 
follow-up. The difference between baseline and follow-up metrics was also obtained for each bootstrap 
sample. Importantly, for this step (i.e. to compute the difference between baseline and follow-up), the same 
subset of bootstrap samples (subset of subjects) was used. These were our bootstrap estimates for baseline, 
12-month follow-up and change values.
 5. Once all bootstrap samples were analysed, distributions of bootstrap estimates were obtained. These were 
then compared against the original estimates and the bootstrap-based 95% CI were obtained for each met-
ric and each group, at baseline and follow-up. Bootstrap-based 95% CI were also obtained for each change 
in the network metric. For the estimation of the change, whenever the 95% CI did not include the null 
value (=0), we assumed the change was significant over time. To compute differences between two groups, 
a 1000 × 1000 matrix was obtained, where all possible combinations of differences between the bootstrap 
estimates (for baseline, follow-up or change parameters) for the two groups were calculated. Original differ-
ences between the two groups that we wanted to compare were then plotted against such 1,000,000-item 
distribution of combinations and combined-bootstrap-based 95% CI were obtained for these original differ-
ences. Whenever these combined-bootstrap-based 95% CIs did not include the null value (=0), we inferred 
significant differences between the two groups for a particular baseline, follow-up or change parameter. All 
these analyses were carried out with MATLAB.
SCN analysis in CIS patients who convert versus those who do not convert to MS during follow up. The same steps 
described above were also applied to assess the 95% CI of baseline, follow-up and change values for the network 
metrics in the two groups of CIS patients with and without early conversion to MS. Different behaviours between 
the two groups in a given network parameter were interpreted as this metric being potentially relevant from a 
clinical point of view.
A post-hoc analysis comparing the networks of patients who were diagnosed with McDonald MS (i.e. either 
they had a second attack or fulfilled the criteria for dissemination in time and space during the follow-up) was 
also performed (results shown in Supplementary Tables 4 and 5).
Data availability. The datasets generated during and/or analysed during the current study are available from 
the corresponding author on reasonable request.
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